Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants ODD for AstraZeneca’s Fasenra to treat EGPA

pharmaceutical-technologyNovember 29, 2018

Tag: FDA , AstraZeneca , EGPA , ODD

PharmaSources Customer Service